Item sold as 0.5mg net peptide.
Fluorogenic substrate for TACE (ADAM17) (between Ala-Val), as well as MMP-3, MMP-7, MMP-12, and MMP-17, but not for ADAM19, MMP-13, nor MMP-14. Similar substrates are also cleaved by ADAM10, ADAM8 and ADAM9, and MMP-1, -2, and -9. This quenched substrate is useful for TACE inhibitor screening and kinetic analysis. Ex: 328 nm, Em: 393 nm, although the following Ex/Em have been used: 320-340/400-420. Also available: OMNIMMP® Fluorogenic Control peptide (BML-P127).
Product Details
| Alternative Name: | ADAM17 substrate |
| |
| Sequence: | Mca-Pro-Leu-Ala-Gln-Ala-Val-Dpa-Arg-Ser-Ser-Ser-Arg-NH2
[Mca=(7-methoxycoumarin-4-yl)acetyl; Dpa=N-3(2,4-dinitrophenyl)-L-α,β-diaminopropionyl] |
| |
| Formula: | C69H103N23O24 |
| |
| MW: | 1638.7 |
| |
| CAS: | 192723-42-5 |
| |
| Purity: | ≥96% |
| |
| Shipping: | Blue Ice |
| |
| Long Term Storage: | -20°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Product Literature References
Serum activity of angiotensin converting enzyme 2 is decreased in patients with acute ischemic stroke: D.M. Bennion, et al.; J. Renin Angiotensin Aldosterone Syst.
17, 1470320316661060 (2016),
Abstract;
Full Text
Related Products
